|
FEM1C expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69390000004377E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.22320000001319E-06 |
| Normal-vs-Stage2 |
7.91789999999848E-05 |
| Normal-vs-Stage3 |
4.38840000005492E-06 |
| Normal-vs-Stage4 |
8.29330000000628E-05 |
| Stage1-vs-Stage2 |
6.989000E-01 |
| Stage1-vs-Stage3 |
7.152800E-01 |
| Stage1-vs-Stage4 |
7.815600E-01 |
| Stage2-vs-Stage3 |
9.161000E-01 |
| Stage2-vs-Stage4 |
9.320000E-01 |
| Stage3-vs-Stage4 |
9.974800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.6483899999975E-05 |
| Normal-vs-AfricanAmerican |
4.35570000000274E-05 |
| Normal-vs-Asian |
3.86980000000037E-06 |
| Caucasian-vs-AfricanAmerican |
3.443800E-01 |
| Caucasian-vs-Asian |
3.154000E-01 |
| AfricanAmerican-vs-Asian |
8.480800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.85299999999611E-05 |
| Normal-vs-Female |
1.60770000001698E-06 |
| Male-vs-Female |
7.371600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.73387999999886E-05 |
| Normal-vs-Age(41-60Yrs) |
3.88389999994576E-06 |
| Normal-vs-Age(61-80Yrs) |
1.60649999969564E-07 |
| Normal-vs-Age(81-100Yrs) |
2.495900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.959800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.906170E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.846400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.672800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.525800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.190800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.586000E-01 |
| Classical-VS-Follicular |
3.583500E-04 |
| Classical-VS-Other |
2.766400E-01 |
| Classical-VS-Normal |
1.204560E-04 |
| Tall-VS-Follicular |
3.484200E-02 |
| Tall-VS-Other |
3.050400E-01 |
| Tall-VS-Normal |
4.401000E-04 |
| Follicular-VS-Other |
9.114200E-01 |
| Follicular-VS-Normal |
6.17959999837936E-08 |
| Other-VS-Normal |
1.894030E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.35210020536204E-10 |
| Normal-vs-N1 |
2.01669999999599E-05 |
| N0-vs-N1 |
5.799200E-01 |
|
|
